Miller B - Search Results

1

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al. Motter R, et al. Among authors: miller b. Ann Neurol. 1995 Oct;38(4):643-8. doi: 10.1002/ana.410380413. Ann Neurol. 1995. PMID: 7574461

2

Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.

Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, Coria F, Chang L, Miller B, Lieberburg I, et al. Vigo-Pelfrey C, et al. Among authors: miller b. Neurology. 1995 Apr;45(4):788-93. doi: 10.1212/wnl.45.4.788. Neurology. 1995. PMID: 7723971

3

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease.

Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P. Galasko D, et al. Among authors: miller b. Neurology. 1997 Mar;48(3):632-5. doi: 10.1212/wnl.48.3.632. Neurology. 1997. PMID: 9065538 Clinical Trial.

4

The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia.

Geschwind D, Karrim J, Nelson SF, Miller B. Geschwind D, et al. Among authors: miller b. Ann Neurol. 1998 Jul;44(1):134-8. doi: 10.1002/ana.410440122. Ann Neurol. 1998. PMID: 9667603 Clinical Trial.

5

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. Galasko D, et al. Among authors: miller b. Arch Neurol. 1998 Jul;55(7):937-45. doi: 10.1001/archneur.55.7.937. Arch Neurol. 1998. PMID: 9678311 Clinical Trial.

6

Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.

Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D, Kramer J, Jagust W, Miller B, Wolkowitz OM, Yaffe K, Weiner MW. Schuff N, et al. Among authors: miller b. Neurology. 2002 Mar 26;58(6):928-35. doi: 10.1212/wnl.58.6.928. Neurology. 2002. PMID: 11914410 Free PMC article.

7

Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease.

Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL. Geschwind MD, et al. Arch Neurol. 2003 Jun;60(6):813-6. doi: 10.1001/archneur.60.6.813. Arch Neurol. 2003. PMID: 12810484

8

Frontotemporal dementia: clinicopathological correlations.

Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, Van Deerlin V, Lee VM, Miller BL, Trojanowski JQ, Grossman M. Forman MS, et al. Ann Neurol. 2006 Jun;59(6):952-62. doi: 10.1002/ana.20873. Ann Neurol. 2006. PMID: 16718704 Free PMC article.

9

Early frontotemporal dementia targets neurons unique to apes and humans.

Seeley WW, Carlin DA, Allman JM, Macedo MN, Bush C, Miller BL, Dearmond SJ. Seeley WW, et al. Ann Neurol. 2006 Dec;60(6):660-7. doi: 10.1002/ana.21055. Ann Neurol. 2006. PMID: 17187353

10

Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.

Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M. Uryu K, et al. J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64. doi: 10.1097/NEN.0b013e31817713b5. J Neuropathol Exp Neurol. 2008. PMID: 18520774 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,566 results

Search Page